Adcock Ingram Company Overview and Performance

Adcock Ingram is a leading pharmaceutical company in South Africa, with a rich history dating back to 1928.

The company was founded by Thomas Adcock and William Ingram, and it has since grown to become one of the largest pharmaceutical companies in the country.

Adcock Ingram's product portfolio includes a wide range of prescription and over-the-counter medicines, as well as vaccines and medical devices.

The company operates in multiple countries across Africa and has a strong presence in the South African market.

If this caught your attention, see: Ingram Barge Company

Adcock Ingram is a company that takes manufacturing and distribution very seriously. They have high-tech facilities in Aeroton and Clayville, producing a wide range of pharmaceutical products.

Their high-volume liquids facility in Clayville is a state-of-the-art, highly automated factory that primarily produces oral liquids and effervescent formulations. This facility is a prime example of Adcock Ingram's commitment to innovation and quality.

The company's distribution network is extensive, with a national footprint that is fully compliant with pharmaceutical standards. They deliver over a million units per trading day through their various distribution centres and/or hubs to hospitals, wholesalers, and other healthcare facilities.

Adcock Ingram's distribution centres offer a range of services, including bulk warehouse storage, direct delivery to healthcare customers, and temperature-sensitive deliveries. They also provide warehousing solutions designed to ensure a consistent storage environment.

Here's a list of some of the countries where Adcock Ingram has a presence:

Our company has a significant global footprint, with operations spread across sub-Saharan Africa. We have manufacturing facilities in South Africa and India, and our head office is located in Midrand, South Africa.

We have a dedicated tablet and capsule facility in Wadeville, South Africa, which focuses primarily on the manufacturing of antiretroviral medicines.

Our Bangalore facility is a joint venture that has a remarkable capacity of 3.5 billion units of tablets and capsules per year. This facility is accredited by several regulatory bodies, including NAFDAC in Nigeria, MHRA in the UK, and SAHPRA in South Africa.

Here is a list of some of the regulatory bodies that have accredited our Bangalore facility:

The distribution network of this Group is impressive, with a fully compliant national footprint that delivers over a million units per trading day to various healthcare providers.

Their extensive distribution centres and/or hubs are strategically located to ensure timely delivery of products to hospitals, wholesalers, the Department of Health, pharmacies, clinics, healthcare practices, and retail outlets.

Bulk warehouse storage is a key service offered by the Group, allowing for efficient storage of large quantities of products.

Direct delivery to healthcare customers is also possible through their fine picking system, which ensures accuracy and speed.

Temperature-sensitive deliveries are handled with care, as are deliveries directly to renal home patients, demonstrating the Group's commitment to customer needs.

Management of customers' returns is also part of their distribution services, showing a focus on customer satisfaction.

Warehousing solutions designed for a consistent storage environment are available, ensuring that products are stored in optimal conditions.

Adcock Ingram has achieved consistent financial growth over the years, with a significant increase in turnover from R6 383 million in 2018 to R7 078 million in the latest period.

Their trading profit has also seen a notable rise, from R850 million in 2018 to R955 million in the latest period.

The company's headline earnings per share (HEPS) have grown from 381.3 cents in 2018 to 421.7 cents in the latest period.

Adcock Ingram has been paying dividends, with a dividend per share (DPS) of 200 cents in the latest period, up from 172 cents in 2018.

The company's net cash position has improved, with a net cash balance of R156 million in 2018 turning into a net cash deficit in the latest period.

Natco Pharma is set to acquire a significant stake in Adcock Ingram Holdings (AIHL) for ₹2,000 crore.

The acquisition is a strategic investment aimed at expanding Natco's geographic footprint in South Africa.

Adcock Ingram Holdings has a diverse product portfolio, including generic and branded formulations, critical-care hospital products, and consumer and home-care products.

Founded in 1890, AIHL operates across four segments: prescription, consumer, OTC, and hospitals.

The acquisition is expected to be completed by 2025.

Post-acquisition, AIHL will continue to operate as a private South African business with Bidvest holding 64.25% and Natco 35.75%, including a prior held 0.80% stake.

This means Natco will consolidate 35.75% of AIHL's net profits in its financial results.

In the financial year June 2024, AIHL clocked revenue of $536 million and profit after tax of $45 million.

Natco's CEO and Vice-Chairman, Rajeev Nannapaneni, sees the proposed transaction as a well-established entry into the Southern African market.

The acquisition will provide Natco with a gateway to the African continent and allow it to tap into new revenue streams.

Natco Pharma Board also approved a proposal to incorporate a wholly owned subsidiary in South Africa with an investment of up to Rs.2,100 crore by this year.

Readers also liked: Simba (South African Company)

Adcock Ingram Holdings Limited is listed on the stock market under the ticker AIP Stock. Its headquarters is located at 1 New Road 7th Street.

The company operates through two main business units: CONSUMER and HOSPITAL. The CONSUMER unit competes in the Fast Moving Consumer Goods (FMCG) space and includes market-leading brands such as Panado and Bioplus.

Adcock Ingram's HOSPITAL portfolio has a long history with Baxter, positioning the company as a leading supplier of critical care products, including intravenous solutions, blood collection products, and renal dialysis systems.

Related reading: Naspers Stock Price

Adcock Ingram Holdings Limited has a history of organization that dates back to 1995, when five divisions comprised the company: critical care, pharmaceuticals, consumer products, wholesale products, and an international division.

The international division was established to manage the company's first marketing foray outside of South Africa.

In 1993, the company's office in Leicester, England was established with a staff of just two people.

Over time, the international division disappeared as a transitional unit, leaving the four core units in place.

Jonathan Louw led the company's pharmaceuticals division from 2002, and later became the firm's CEO in 2006.

Here's a brief overview of the company's Board of Directors:

As we explore the company structure of Adcock Ingram Holdings Limited, it's essential to understand who its key shareholders are.

The company's shareholders are primarily made up of large corporations and financial institutions.

One of the largest shareholders is THE BIDVEST GROUP LIMITED, holding 56.05% of the company's equities.

Worth a look: Meyer Brothers Drug Company

Another significant shareholder is Public Investment Corporation (SOC) Ltd., owning 8.379% of the company's equities.

Other notable shareholders include Old Mutual Customised Solutions (Pty) Ltd. and Centaur Asset Management Pty Ltd., holding 0.6745% and 0.4602% respectively.

Here's a breakdown of the top shareholders:

Adcock Ingram is a pharmaceutical company that offers a wide range of products, including Adco-Alzam and Adco-Ciprin, which are part of their extensive portfolio of generic medicines.

Their hospital business is also notable, supplying critical care products such as Sabax Intravenous Fluids and Gambro Haemodialysis systems.

In the consumer space, Adcock Ingram competes with market-leading brands like Panado, which is known for its headache relief tablets and syrup.

Adcock Ingram's products include a variety of medicines, such as Alcophyllex and Aldomet, which are used to treat different conditions.

Here are some of the products they offer:

The pharmaceutical industry is a crucial part of the healthcare sector, providing a wide range of medicines to treat various ailments. Adco-Alzam, a medication for anxiety, is one such product.

Adco-Alzam is just one of many pharmaceutical products offered by Adco. Their portfolio includes Adco-Ciprin, a pain reliever, and Adco-Dermed, a skin cream. These products demonstrate the company's commitment to providing affordable and effective solutions for common health issues.

One notable product in Adco's range is Panado, a tablet for headache relief. It's a popular choice among those seeking quick and easy pain management. Panado Syrup is also available for those who prefer a liquid form.

The pharmaceutical industry is constantly evolving, with new products and treatments being developed all the time. Adco's extensive range of generic antiretroviral products is a testament to this. These products are designed to make life-saving treatments more accessible to those who need them.

Here's a list of some of the notable pharmaceutical products offered by Adco:

Adcock Ingram has a strong presence in the hospital business, thanks to its long history with Baxter. This partnership positions Adcock Ingram as a leading supplier of critical care products.

One of the key areas where Adcock Ingram excels is in intravenous solutions, blood collection products, and renal dialysis systems. These are critical components in hospitals, and Adcock Ingram's expertise in these areas is unmatched.

Some of the notable products in Adcock Ingram's hospital business portfolio include Sabax Intravenous Fluids, Gambro Haemodialysis, and Colleague Infusion Pumps. These products are designed to meet the specific needs of hospitals and healthcare professionals.

Here are some of the key products in Adcock Ingram's hospital business portfolio:

The AICC facility has undergone significant upgrades, with a major project completed in May 2012 that invested around ZAR300m ($37m) in improving machinery and equipment.

This investment aimed to boost the plant's operational efficiency, which is essential for any industrial operation looking to stay competitive.

The AICC facility has scope for future production expansions, making it a great option for businesses looking to grow or expand their operations.

Adcock Ingram's facilities are truly impressive, and I'm excited to share some of the key facts with you.

The company's Critical Care facility in Aeroton produces a range of life-saving products, including intravenous fluids, blood bags, and renal dialysis products.

Located on a 10ha site in Aeroton, the facility covers a massive 25,286m² and has a 12,609m² production area.

The facility also boasts 7,144m² of warehouse space, 783m² of QC block, 1,473m² of amenities, and 3,277m² of administrative offices.

The Critical Care Factory has a highly automated factory in Clayville that primarily produces oral liquids and effervescent formulations.

The factory produces a range of products, including Vacoliter in glass bottles of capacities 200ml, 500ml, and 1,000ml, and Viaflex, also called IV / Peritoneal Dialysis Solutions, in various container sizes.

The plant incorporates several sustainable features, such as recycling of about 100,000l of water a day, sensor-based lighting equipment, and solar-powered water heaters for personal use.

The upgraded facility in Aeroton enabled Adcock Ingram to meet international standards, including those of the PIC/S and WHO, and has facilitated partnerships with dialysis providers and product distributors in the country.